Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]
- Market Cap ₹ 3,582 Cr.
- Current Price ₹ 228
- High / Low ₹ 283 / 133
- Stock P/E
- Book Value ₹ 258
- Dividend Yield 0.00 %
- ROCE -0.73 %
- ROE -1.84 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.89 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -1.28% over last 3 years.
- Earnings include an other income of Rs.45.4 Cr.
- Company has high debtors of 205 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Microcap 250 BSE Allcap BSE Healthcare Nifty Total Market BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|
0 | 7 | 451 | 474 | 549 | 581 | 200 | 307 | 403 | 327 | 395 | |
0 | 5 | 303 | 308 | 356 | 401 | 253 | 267 | 394 | 321 | 352 | |
Operating Profit | -0 | 2 | 148 | 166 | 194 | 179 | -53 | 40 | 9 | 7 | 43 |
OPM % | 25% | 33% | 35% | 35% | 31% | -26% | 13% | 2% | 2% | 11% | |
0 | 0 | 71 | 66 | 72 | 64 | 59 | 53 | 49 | 60 | 45 | |
Interest | 1 | 1 | 39 | 35 | 47 | 47 | 34 | 37 | 58 | 68 | 64 |
Depreciation | 0 | 0 | 136 | 134 | 136 | 141 | 141 | 140 | 96 | 102 | 85 |
Profit before tax | -0 | 1 | 44 | 62 | 82 | 55 | -169 | -84 | -96 | -103 | -61 |
Tax % | 0% | 12% | 45% | 40% | 31% | 31% | 38% | -63% | -39% | -26% | |
-0 | 1 | 24 | 37 | 56 | 39 | -233 | -32 | -59 | -76 | -39 | |
EPS in Rs | 2.30 | 3.47 | 2.46 | -14.85 | -2.01 | -3.75 | -4.87 | -2.45 | |||
Dividend Payout % | 0% | 0% | 0% | 0% | 6% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -10% |
3 Years: | 18% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 19% |
TTM: | 1% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 0% |
1 Year: | 35% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -1% |
Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.05 | 0.05 | 0.00 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 |
Reserves | -1 | 0 | 4,771 | 4,759 | 4,860 | 4,764 | 4,643 | 4,200 | 4,083 | 4,021 | 4,014 |
10 | 9 | 445 | 622 | 584 | 573 | 538 | 535 | 593 | 536 | 605 | |
3 | 3 | 321 | 394 | 339 | 366 | 339 | 448 | 473 | 488 | 457 | |
Total Liabilities | 12 | 12 | 5,537 | 5,807 | 5,816 | 5,735 | 5,552 | 5,214 | 5,181 | 5,077 | 5,108 |
0 | 0 | 1,927 | 1,853 | 1,715 | 1,633 | 1,510 | 1,356 | 1,382 | 1,416 | 1,388 | |
CWIP | 0 | 0 | 41 | 48 | 70 | 89 | 121 | 118 | 143 | 74 | 80 |
Investments | 0 | 0 | 2,761 | 2,937 | 2,907 | 2,900 | 2,882 | 3,032 | 2,913 | 2,848 | 2,850 |
12 | 12 | 808 | 969 | 1,124 | 1,113 | 1,039 | 708 | 743 | 739 | 790 | |
Total Assets | 12 | 12 | 5,537 | 5,807 | 5,816 | 5,735 | 5,552 | 5,214 | 5,181 | 5,077 | 5,108 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
-1 | 3 | 270 | 20 | 120 | 197 | -2 | 227 | -53 | 24 | |
0 | 0 | -16 | -175 | -24 | -74 | 62 | -173 | 41 | 97 | |
1 | -2 | -225 | 142 | -85 | -124 | -71 | -46 | 1 | -131 | |
Net Cash Flow | -0 | 1 | 29 | -12 | 10 | -2 | -10 | 9 | -11 | -10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0 | 58 | 108 | 86 | 91 | 217 | 78 | 133 | 205 | |
Inventory Days | 390 | 397 | 500 | 390 | 690 | 723 | 389 | 534 | ||
Days Payable | 149 | 207 | 210 | 157 | 204 | 198 | 182 | 365 | ||
Cash Conversion Cycle | 0 | 298 | 298 | 376 | 324 | 703 | 604 | 340 | 374 | |
Working Capital Days | 467 | 278 | 288 | 284 | 230 | 785 | 362 | 267 | 351 | |
ROCE % | 21% | 3% | 2% | 2% | 2% | -2% | -1% | -1% | -1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
20 Nov - Transcript of earnings conference call for Q2 FY '25.
-
Announcement under Regulation 30 (LODR)-Change in Management
19 Nov - Appointment of Mr. Rajkumar Mirajgave as VP (Quality).
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14 Nov - Audio recording of earnings conference call available.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
14 Nov - Investors presentation on Q2 and H1 FY25 results.
-
OUTCOME OF BOARD MEETING ALONGWITH UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30/09/2024
13 Nov - Approval of Q2 and half-year financial results.
Annual reports
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Sep 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
Business Segments & Revenue Contribution